ストックスクリーナーアプリを入手
0.9827
3.66%
-0.0373
プレマーケット:
.93
-0.0527
-5.36%
前日終値:
$1.02
開ける：
$1.02
24時間の取引高:
106.27K
Relative Volume:
0.30
時価総額：
$6.48M
収益：
-
当期純損益:
$-5.85M
株価収益率:
-0.1469
EPS:
-6.6877
ネットキャッシュフロー:
$-8.00M
1週間 パフォーマンス:
-7.29%
1か月 パフォーマンス:
+35.54%
6か月 パフォーマンス:
-40.80%
1年 パフォーマンス:
-89.08%
1日の値動き範囲:
$0.94
$1.05
1週間の範囲:
$0.94
$1.05
52週間の値動き範囲:
$0.6427
$15.06
Alzamend Neuro Inc Stock (ALZN) Company Profile
ALZN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALZN
Alzamend Neuro Inc
|
0.9827 | 6.48M | 0 | -5.85M | -8.00M | -6.6877 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-10-01 | 開始されました | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc (ALZN) 最新ニュース
Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Update - Defense World
Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March? - Insider Monkey
Alzamend neuro director William Horne buys $3,285 in common stock By Investing.com - Investing.com Australia
Alzamend neuro director William Horne buys $3,285 in common stock - Investing.com India
Alzamend Neuro director Milton Ault buys $2,968 in company stock - Investing.com India
Alzamend Neuro director Milton Ault buys $2,968 in company stock By Investing.com - Investing.com South Africa
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital - The Manila Times
Major Breakthrough: New Alzheimer's Drug Advances to Phase II at Top Hospital - Stock Titan
Alzamend Neuro CFO David Katzoff acquires $5,048 in common stock By Investing.com - Investing.com Australia
Alzamend Neuro CFO David Katzoff acquires $5,048 in common stock - Investing.com
Alzamend Neuro director William B. Horne purchases $4,891 in shares - Investing.com India
Alzamend Neuro director William B. Horne purchases $4,891 in shares By Investing.com - Investing.com UK
Alzamend Neuro director William B. Horne buys $4,851 in stock - Investing.com India
Alzamend Neuro director William B. Horne buys $4,851 in stock By Investing.com - Investing.com South Africa
Alzamend Neuro director Milton C. Ault III acquires $4,810 in shares - Investing.com Australia
Alzamend Neuro director Milton C. Ault III acquires $4,810 in shares By Investing.com - Investing.com South Africa
Alzamend Neuro, Inc. Plans Phase II Clinical Study of AL001 in Major Depressive Disorder to Compare Lithium Delivery with Marketed Products - Nasdaq
Alzamend Neuro Announces Initiation Date of Phase II - GlobeNewswire
Major Depression Breakthrough: New Lithium Treatment Heads to Phase II at Top Hospital - StockTitan
Alzamend Neuro (ALZN) Projected to Post Earnings on Monday - Defense World
Alzamend Neuro director Milton Ault buys $68 in stock By Investing.com - Investing.com Australia
Alzamend Neuro director Milton Ault buys $68 in stock - Investing.com
Short Interest in Alzamend Neuro, Inc. (NASDAQ:ALZN) Rises By 332.2% - Defense World
Alzamend Neuro stock hits 52-week low at $0.68 amid sharp decline - Investing.com Australia
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital - BioSpace
Alzamend Neuro stock hits 52-week low at $0.68 amid sharp decline By Investing.com - Investing.com South Africa
Alzamend Neuro plans mid-stage study of its therapy for PTSD in fourth-quarter 2025 - Marketscreener.com
Major PTSD Breakthrough: New Lithium Treatment Heads to Phase II Trial at Top Hospital - StockTitan
EXCLUSIVE: Alzamend Neuro To Launch Phase 2 Study For Lead Drug For PTSD Patients In Late 2025 To Assess Lithium Delivery Benefits - Benzinga
Alzamend Neuro Inc. (ALZN) reports earnings - Quartz
Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Down 33.0% in February - Defense World
Alzamend Neuro Announces Initiation Date Of Phase II Clinical Trial Of AL001 For Treatment Of Bipolar Disorder To Take Place At Massachusetts General Hospital - Marketscreener.com
Alzamend Neuro announces initiation date of Phase II trial of AL001 - TipRanks
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital - The Manila Times
Alzamend Neuro Announces Phase II Clinical Study of AL001 for Bipolar Disorder Expected to Start in Q3 2025 - Nasdaq
Alzamend Neuro Plans Phase II Trial for Advanced Lithium Treatment in Bipolar Disorder | ALZN Stock News - StockTitan
Alzamend Neuro Announces Bylaws Amendment and New Stock Series By Investing.com - Investing.com South Africa
Alzamend Neuro Announces Bylaws Amendment and New Stock Series - Investing.com
Alzamend Neuro stock hits 52-week low at $0.81 amid sharp decline - Investing.com Australia
Alzamend Neuro inks deal for equity securities sale By Investing.com - Investing.com South Africa
Alzamend Neuro inks deal for equity securities sale - Investing.com
Alzamend Neuro Inc (ALZN) 財務データ
収益
当期純利益
現金流量
EPS
3.01%
大文字化:
|
ボリューム (24 時間):